According to SNS Insider, Biosimilars Market Poised for Exponential Growth, Driven by Cost Savings and Increasing Chronic Disease Burden

AUSTIN, TEXAS, UNITED STATES, January 10, 2024 /EINPresswire.com/ -- The Biosimilars Market, as per the SNS Insider report, achieved a valuation of USD 25.10 billion in 2022, with projections indicating a substantial growth to reach USD 91.81 billion by 2030. The anticipated compound annual growth rate (CAGR) for the forecast period spanning from 2023 to 2030 is 17.6%.

𝐊𝐞𝐲 𝐅𝐚𝐜𝐭𝐨𝐫𝐬 𝐃𝐫𝐢𝐯𝐢𝐧𝐠 𝐭𝐡𝐞 𝐁𝐢𝐨𝐬𝐢𝐦𝐢𝐥𝐚𝐫𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐠𝐫𝐨𝐰𝐭𝐡:

Patent expirations on high-cost biologics: As patents expire on some of the world's most expensive drugs, biosimilars offer a cost-effective alternative, potentially generating billions of dollars in savings for healthcare systems.

Rising healthcare costs: Healthcare costs are rising globally, putting pressure on governments and insurers to find more affordable treatment options. Biosimilars offer a viable solution by reducing medication costs.

Increasing prevalence of chronic diseases: The growing burden of chronic diseases like cancer, diabetes, and autoimmune disorders is creating a significant demand for effective and affordable treatments. Biosimilars can play a crucial role in meeting this demand.
Supportive regulatory environment: Regulatory agencies worldwide are increasingly streamlining the approval process for biosimilars, further boosting market growth.

Growing awareness and acceptance: Patients and healthcare professionals are becoming increasingly aware of the benefits of biosimilars, leading to higher adoption rates.

𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐩𝐨𝐫𝐭 𝐒𝐜𝐨𝐩𝐞

Biosimilars represent a revolutionary category of pharmaceuticals designed to mimic the biological structures and functions of existing biologic drugs. These complex molecules are highly similar to their reference products, such as monoclonal antibodies and therapeutic proteins, yet they offer a more cost-effective alternative. One of the primary driving factors behind the growing prominence of biosimilars is the increasing demand for affordable and accessible biologic treatments.

𝐆𝐞𝐭 𝐅𝐫𝐞𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐨𝐟 𝐁𝐢𝐨𝐬𝐢𝐦𝐢𝐥𝐚𝐫𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐩𝐨𝐫𝐭: https://www.snsinsider.com/sample-request/2941

𝐌𝐚𝐫𝐤𝐞𝐭 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬

The biosimilars market is propelled by several robust growth drivers, ensuring its sustained expansion and influence within the pharmaceutical landscape. The relentless pursuit of cost-effective treatment options, coupled with regulatory support, has established a fertile ground for the market to flourish. The economic advantage of biosimilars over originator biologics is a key driver, attracting healthcare providers, payers, and patients seeking affordable treatment options. The imminent expiry of patents for several blockbuster biologics is creating opportunities for biosimilar developers to enter the market with competitive offerings. The increasing prevalence of chronic diseases necessitates cost-effective therapeutic solutions, driving the demand for biosimilars in disease management.

𝐒𝐨𝐦𝐞 𝐨𝐟 𝐌𝐚𝐣𝐨𝐫 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 𝐋𝐢𝐬𝐭𝐞𝐝 𝐢𝐧 𝐭𝐡𝐞 𝐁𝐢𝐨𝐬𝐢𝐦𝐢𝐥𝐚𝐫𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐩𝐨𝐫𝐭 𝐚𝐫𝐞:

• Dr Reddy’s Laboratories
• Eli Lilly and Company
• Pfizer Inc.
• Intas Pharmaceutical Ltd
• Biocon Ltd
• Merck & Co. Inc.
• Amgen Inc.
• Teva Pharmaceutical Industries Limited
• Kashiv BioSciences
• Reliance life sciences

𝐊𝐞𝐲 𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐬 𝐜𝐨𝐯𝐞𝐫𝐞𝐝 𝐢𝐧 𝐭𝐡𝐞 𝐦𝐚𝐫𝐤𝐞𝐭:

By Type
• Human growth hormone
• Erythropoietin
• Monoclonal antibodies
• Insulin
• Granulocyte-Colony Stimulating Factor

By Application
• Blood disorders
• Oncology diseases
• Chronic and autoimmune diseases

𝐈𝐦𝐩𝐚𝐜𝐭 𝐨𝐟 𝐑𝐞𝐜𝐞𝐬𝐬𝐢𝐨𝐧

The biosimilars market, while resilient, faces the dual challenges of economic recession and global healthcare uncertainties. The impact of the ongoing recession on the market is nuanced, with both positive and negative implications. Recession-driven cost-consciousness may boost the adoption of biosimilars as cost-effective alternatives, especially in regions grappling with economic downturns. Economic uncertainties may pose challenges in funding for biosimilar development, potentially slowing down research and innovation in the sector.

𝐈𝐦𝐩𝐚𝐜𝐭 𝐨𝐟 𝐑𝐮𝐬𝐬𝐢𝐚-𝐔𝐤𝐫𝐚𝐢𝐧𝐞 𝐖𝐚𝐫

The Russia-Ukraine war has sent shockwaves across global markets, and the biosimilars sector is not immune to its far-reaching consequences. The impact on the biosimilars market is contingent upon geopolitical and economic factors. Geopolitical tensions can disrupt the global supply chain for biosimilar manufacturing, potentially leading to shortages and delays in production. Uncertainties resulting from the conflict may trigger market volatility, impacting investor confidence and influencing the pace of biosimilar development and commercialization.

𝐍𝐞𝐞𝐝 𝐂𝐮𝐬𝐭𝐨𝐦𝐢𝐳𝐞𝐝 𝐑𝐞𝐩𝐨𝐫𝐭 𝐚𝐬 𝐩𝐞𝐫 𝐘𝐨𝐮𝐫 𝐁𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐑𝐞𝐪𝐮𝐢𝐫𝐞𝐦𝐞𝐧𝐭 𝐀𝐬𝐤 𝐇𝐞𝐫𝐞: https://www.snsinsider.com/enquiry/2941

𝐊𝐞𝐲 𝐑𝐞𝐠𝐢𝐨𝐧𝐚𝐥 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭

The North American biosimilars market is thriving, driven by a robust regulatory framework, increasing acceptance of biosimilars among healthcare providers, and the urgency to curb rising healthcare costs. Market players are strategically navigating patent expirations and forging partnerships to capitalize on the region's growing demand for cost-effective biologics. Europe remains a frontrunner in biosimilar adoption, with well-established regulatory pathways and a history of successful market penetration. The European market is characterized by a competitive landscape, fostering innovation and affordability in the region's healthcare systems. The Asia-Pacific market is experiencing exponential growth, propelled by rising healthcare needs, expanding biopharmaceutical capabilities, and supportive government initiatives.

𝐊𝐞𝐲 𝐓𝐚𝐤𝐞𝐚𝐰𝐚𝐲 𝐟𝐫𝐨𝐦 𝐁𝐢𝐨𝐬𝐢𝐦𝐢𝐥𝐚𝐫𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐒𝐭𝐮𝐝𝐲

• The human growth hormone (HGH) segment stands poised to dominate the market, driven by its critical role in treating growth disorders and hormonal deficiencies. The increasing prevalence of growth-related disorders, coupled with the need for cost-effective treatment options, positions HGH biosimilars as a cornerstone in the market's therapeutic landscape.
• Within the biosimilars market, the blood disorders segment emerges as a dominant force. The demand for biosimilar alternatives for blood-related conditions, such as anemia and clotting disorders, is on the rise. Enhanced patient access, coupled with the economic advantage of biosimilars, is propelling the blood disorders segment to the forefront of biosimilar therapeutic advancements.

𝐑𝐞𝐜𝐞𝐧𝐭 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭𝐬 𝐑𝐞𝐥𝐚𝐭𝐞𝐝 𝐭𝐨 𝐁𝐢𝐨𝐬𝐢𝐦𝐢𝐥𝐚𝐫𝐬 𝐌𝐚𝐫𝐤𝐞𝐭

• In a groundbreaking move, CVS, a stalwart in the healthcare industry, has launched a cutting-edge biosimilars brand, marking a significant stride in the realm of pharmaceuticals. The newly introduced biosimilars brand by CVS is poised to provide patients with more cost-effective alternatives to existing biologics, ensuring a wider demographic can benefit from these crucial treatments.
• In a strategic and forward-looking collaboration, Meitheal, a prominent player in the pharmaceutical domain, has forged a partnership with a leading Chinese company for the licensing of insulin biosimilars in the United States. This collaboration heralds a new era in the availability of insulin treatments, reflecting Meitheal's dedication to addressing critical healthcare needs through international partnerships.

𝐁𝐮𝐲 𝐁𝐢𝐨𝐬𝐢𝐦𝐢𝐥𝐚𝐫𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐩𝐨𝐫𝐭: https://www.snsinsider.com/checkout/2941

𝐓𝐚𝐛𝐥𝐞 𝐨𝐟 𝐂𝐨𝐧𝐭𝐞𝐧𝐭𝐬

Chapter 1: Introduction
1.1 Background
1.2 Objectives of the Study
1.3 Scope and Limitations
1.4 Research Questions
1.5 Significance of the Study

Chapter 2: Research Methodology
2.1 Research Design
2.2 Data Collection Methods
2.3 Sampling Techniques
2.4 Data Analysis
2.5 Ethical Considerations

Chapter 3: Biosimilars Market Dynamics
3.1 Market Overview
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Trends

Chapter 4: Impact Analysis
4.1 COVID-19
4.2 Ukraine-Russia War
4.3 Ongoing Recession on Major Economies

Chapter 5: Value Chain Analysis

Chapter 6: Porter’s 5 Forces Model

Chapter 7: PEST Analysis

Chapter 8: Biosimilars Market Segmentation, By Type

Chapter 9: Biosimilars Market Segmentation, By Application

Chapter 10: Biosimilars Market Segmentation, By End Use

Chapter 11: Regional Analysis

Chapter 12: Company Profile

Chapter 13: Competitive Landscape

Chapter 14: Use Case and Best Practices

Chapter 15: Conclusion

Akash Anand
SNS Insider Pvt. Ltd
+1 415-230-0044
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn
Instagram
YouTube